Yoshiaki Tadokoro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yoshiaki Tadokoro has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Daisuke Takeda
Department of Oral and Maxillofacial Surgery, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan
3 shared publications - Masaya Akashi
Department of Oral and Maxillofacial Surgery, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan
3 shared publications - Yasumasa Kakei
Department of Oral and Maxillofacial Surgery, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan
3 shared publications - Izumi Saito
Department of Oral and Maxillofacial Surgery, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan
2 shared publications - Nanae Yatagai
Department of Oral and Maxillofacial Surgery, Kobe University Graduate School of Medicine Kobe Japan
2 shared publications - Takumi Hasegawa
Department of Oral and Maxillofacial Surgery, Kobe University Graduate School of Medicine, Kobe, Japan
2 shared publications
Latest Publications
- Open Access
Expression of Mitophagy-Associated Factors and Their Associations with Metastasis and Prognosis in Oral Squamous Cell Carcinoma
Background/Objectives: Mitophagy-associated factors have been implicated in tumor behavior and patient outcomes; however, their clinical significance depends on tumor type, stage, and microenvironmental context, and consistent conclusions remain lacking. We aimed to comprehensively assess the expression of mitophagy-associated factors in a moderate-sized cohort of patients with oral squamous cell carcinoma (OSCC) and clarify their prognostic significance. Methods: A retrospective cohort study included 197 patients with OSCC who underwent primary surgical resection between August 2013 and October 2018. Immunohistochemical expression of mitophagy-associated factors, including transcription factor EB (TFEB), nuclear factor erythroid 2-related factor 2 (NRF2), activating transcription factor 4 (ATF4), Parkin, PTEN-induced kinase 1 (PINK1), and mitochondrial ubiquitin ligase (MITOL), was evaluated. Associations between protein expression and clinicopathological parameters, local control, 5-year disease-specific survival (DSS), regional control, and distant metastasis were analyzed. Results: High expression of NRF2 and TFEB was significantly related with decreased DSS, poor regional control, and increased distant metastasis. High ATF4 expression was associated with distant metastasis and showed no association with DSS. Parkin, PINK1, and MITOL showed no significant association with patient outcomes. Explanatory multivariable analysis showed associations between high TFEB expression, vascular invasion, extranodal extension, and disease-specific mortality. Conclusions: TFEB expression showed an exploratory association with aggressive tumor behavior and poor prognosis in OSCC, warranting further investigation. However, because immunohistochemical evaluation measures protein expression rather than mitophagy flux or mitochondrial turnover, these findings represent associations between mitophagy-associated factor expression and clinical outcomes and do not directly demonstrate altered mitophagy activity.
Open AccessExpression of Mitophagy-Associated Factors and Their Associations with Metastasis and Prognosis in Oral Squamous Cell Carcinoma
Background/Objectives: Mitophagy-associated factors have been implicated in tumor behavior and patient outcomes; however, their clinical significance depends on tumor type, stage, and microenvironmental context, and consistent conclusions remain lacking. We aimed to comprehensively assess the expression of mitophagy-associated factors in a moderate-sized cohort of patients with oral squamous cell carcinoma (OSCC) and clarify their prognostic significance. Methods: A retrospective cohort study included 197 patients with OSCC who underwent primary surgical resection between August 2013 and October 2018. Immunohistochemical expression of mitophagy-associated factors, including transcription factor EB (TFEB), nuclear factor erythroid 2-related factor 2 (NRF2), activating transcription factor 4 (ATF4), Parkin, PTEN-induced kinase 1 (PINK1), and mitochondrial ubiquitin ligase (MITOL), was evaluated. Associations between protein expression and clinicopathological parameters, local control, 5-year disease-specific survival (DSS), regional control, and distant metastasis were analyzed. Results: High expression of NRF2 and TFEB was significantly related with decreased DSS, poor regional control, and increased distant metastasis. High ATF4 expression was associated with distant metastasis and showed no association with DSS. Parkin, PINK1, and MITOL showed no significant association with patient outcomes. Explanatory multivariable analysis showed associations between high TFEB expression, vascular invasion, extranodal extension, and disease-specific mortality. Conclusions: TFEB expression showed an exploratory association with aggressive tumor behavior and poor prognosis in OSCC, warranting further investigation. However, because immunohistochemical evaluation measures protein expression rather than mitophagy flux or mitochondrial turnover, these findings represent associations between mitophagy-associated factor expression and clinical outcomes and do not directly demonstrate altered mitophagy activity.
- Open Access
- 22 January 2026
- Published by Springer Nature in Journal of Bone and Mineral Metabolism
- Vol. 44 (3) , 346-353
Identifying the clinical indicator for surgical intervention in medication-related osteonecrosis of the jaw
Introduction: Surgery has increasingly been reported as an effective treatment for medication-related osteonecrosis of the jaw (MRONJ), but concrete intervention criteria are lacking. On computed tomography (CT) images, the boundary between the healthy site and necrotic lesion, which we defined as “MRONJ demarcation line”, is sometimes visible. This study aimed to identify the factors associated with this boundary to improve surgical planning. Materials and methods: 95 patients with MRONJ who underwent their first CT at our institution between May 2010 and June 2022 were included. The Mann–Whitney U test, Fisher’s exact test, and multivariate logistic regression analysis were performed. The cumulative incidence rates were calculated using the Kaplan–Meier method. Statistical significance was set at p < 0.05. Results: MRONJ demarcation line was observed in 63 patients and absent in 32. Significant associations were identified between MRONJ demarcation line formation and denosumab ( p = 0.013), antiresorptive agent (ARA) discontinuation ( p = 0.024), and periosteal reaction ( p = 0.034). The cumulative incidence rates of MRONJ demarcation line formation at 12, 24, and 36 months after discontinuation of high-dose ARA were 58.0%, 89.2%, and 96.4% for denosumab, and 29.9%, 68.8%, and 88.3% for bisphosphonates, respectively. In the low-dose group, the rates at 12, 24, and 36 months after discontinuation of denosumab were 41.7%, 51.4%, and 63.5%, respectively, while those for bisphosphonates were 22.2%, 35.8%, and 51.1%. Conclusion: Denosumab administration, ARA discontinuation, and periosteal reaction are significantly associated with the MRONJ demarcation line, which may help in establishing criteria for surgical intervention.
- 22 January 2026
- Published by Springer Nature in Journal of Bone and Mineral Metabolism
- Vol. 44 (3) , 346-353
Open AccessIdentifying the clinical indicator for surgical intervention in medication-related osteonecrosis of the jaw
Introduction: Surgery has increasingly been reported as an effective treatment for medication-related osteonecrosis of the jaw (MRONJ), but concrete intervention criteria are lacking. On computed tomography (CT) images, the boundary between the healthy site and necrotic lesion, which we defined as “MRONJ demarcation line”, is sometimes visible. This study aimed to identify the factors associated with this boundary to improve surgical planning. Materials and methods: 95 patients with MRONJ who underwent their first CT at our institution between May 2010 and June 2022 were included. The Mann–Whitney U test, Fisher’s exact test, and multivariate logistic regression analysis were performed. The cumulative incidence rates were calculated using the Kaplan–Meier method. Statistical significance was set at p < 0.05. Results: MRONJ demarcation line was observed in 63 patients and absent in 32. Significant associations were identified between MRONJ demarcation line formation and denosumab ( p = 0.013), antiresorptive agent (ARA) discontinuation ( p = 0.024), and periosteal reaction ( p = 0.034). The cumulative incidence rates of MRONJ demarcation line formation at 12, 24, and 36 months after discontinuation of high-dose ARA were 58.0%, 89.2%, and 96.4% for denosumab, and 29.9%, 68.8%, and 88.3% for bisphosphonates, respectively. In the low-dose group, the rates at 12, 24, and 36 months after discontinuation of denosumab were 41.7%, 51.4%, and 63.5%, respectively, while those for bisphosphonates were 22.2%, 35.8%, and 51.1%. Conclusion: Denosumab administration, ARA discontinuation, and periosteal reaction are significantly associated with the MRONJ demarcation line, which may help in establishing criteria for surgical intervention.
- Open Access
- 13 November 2023
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 12 (1) , e50500
The Efficacy of Carbon Dioxide Paste in Alleviating Pain in Patients After Neck Dissection: Protocol for a Double-Blinded, Randomized Controlled Trial
Background: Head and neck cancers that cause severe aesthetic and functional disorders normally metastasize to the cervical lymph nodes. Patients with cervical lymph node metastasis are undergoing neck dissection. Shoulder complaints are common after neck dissection, with patients reporting symptoms such as pain, weakness, shoulder droop, and disability. However, no safe and effective treatment is available for this condition at present. We will conduct a double-blinded, randomized controlled trial to evaluate the efficacy of carbon dioxide (CO2) paste in relieving pain in patients after neck dissection. Objective: This will be the first clinical study to compare the efficacy of CO2 paste with placebo in relieving postoperative pain in patients who underwent neck dissection. Methods: We will perform this trial at the Kobe University Hospital in Japan. Patients will be randomized 1:1 into the CO2 paste and control groups. Patients in the CO2 paste group will have the CO2 paste applied to the cervical surface skin for 10 minutes once per day for 14 consecutive days. The primary end point of the study is a change in the visual analog scale (VAS) scores of neck pain from baseline on day 1 (preapplication) to the end of drug application (day 15). Secondary end points include changes in the following parameters from baseline on day 1 to the end of drug application (day 15) or the study (day 29): neck pain VAS score (days 1-29), grip strength (days 1-15 and 1-29), VAS scores for subjective symptoms (the feeling of strangulation, numbness, swelling, and warmth in the neck and shoulder region) for days 1-15 and 1-29, whether the VAS score improved more than 30% (days 1-15), the arm abduction test (days 1-15 and 1-29), shoulder range of motion (abduction and flexion) for days 1-15 and 1-29, occurrence of skin disorders, and occurrence of serious side effects. Periodic monitoring will be conducted for participants during the trial. This study was approved by the certified review board of Kobe University. Results: The intervention commenced in May 2021 and will continue until March 2024. The collected data will provide information on the efficacy of the CO2 paste treatment. The primary end point will be compared using the Wilcoxon test, with the 1-sided significance level set at 5%. Each evaluation item will be summarized. Secondary efficacy end points will be analyzed to provide additional insights into the primary analysis. Findings based on the treatment effects are expected to be submitted for publication in 2025. Conclusions: This trial will provide exploratory evidence of the efficacy and safety of CO2 paste in relieving pain in patients after neck dissection. Trial Registration: Japan Registry of Clinical Trials (jRCT) identifier: jRCTs051210028; https://jrct.niph.go.jp/en-latest-detail/jRCTs051210028 International Registered Report Identifier (IRRID): DERR1-10.2196/50500
- 13 November 2023
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 12 (1) , e50500
Open AccessThe Efficacy of Carbon Dioxide Paste in Alleviating Pain in Patients After Neck Dissection: Protocol for a Double-Blinded, Randomized Controlled Trial
Background: Head and neck cancers that cause severe aesthetic and functional disorders normally metastasize to the cervical lymph nodes. Patients with cervical lymph node metastasis are undergoing neck dissection. Shoulder complaints are common after neck dissection, with patients reporting symptoms such as pain, weakness, shoulder droop, and disability. However, no safe and effective treatment is available for this condition at present. We will conduct a double-blinded, randomized controlled trial to evaluate the efficacy of carbon dioxide (CO2) paste in relieving pain in patients after neck dissection. Objective: This will be the first clinical study to compare the efficacy of CO2 paste with placebo in relieving postoperative pain in patients who underwent neck dissection. Methods: We will perform this trial at the Kobe University Hospital in Japan. Patients will be randomized 1:1 into the CO2 paste and control groups. Patients in the CO2 paste group will have the CO2 paste applied to the cervical surface skin for 10 minutes once per day for 14 consecutive days. The primary end point of the study is a change in the visual analog scale (VAS) scores of neck pain from baseline on day 1 (preapplication) to the end of drug application (day 15). Secondary end points include changes in the following parameters from baseline on day 1 to the end of drug application (day 15) or the study (day 29): neck pain VAS score (days 1-29), grip strength (days 1-15 and 1-29), VAS scores for subjective symptoms (the feeling of strangulation, numbness, swelling, and warmth in the neck and shoulder region) for days 1-15 and 1-29, whether the VAS score improved more than 30% (days 1-15), the arm abduction test (days 1-15 and 1-29), shoulder range of motion (abduction and flexion) for days 1-15 and 1-29, occurrence of skin disorders, and occurrence of serious side effects. Periodic monitoring will be conducted for participants during the trial. This study was approved by the certified review board of Kobe University. Results: The intervention commenced in May 2021 and will continue until March 2024. The collected data will provide information on the efficacy of the CO2 paste treatment. The primary end point will be compared using the Wilcoxon test, with the 1-sided significance level set at 5%. Each evaluation item will be summarized. Secondary efficacy end points will be analyzed to provide additional insights into the primary analysis. Findings based on the treatment effects are expected to be submitted for publication in 2025. Conclusions: This trial will provide exploratory evidence of the efficacy and safety of CO2 paste in relieving pain in patients after neck dissection. Trial Registration: Japan Registry of Clinical Trials (jRCT) identifier: jRCTs051210028; https://jrct.niph.go.jp/en-latest-detail/jRCTs051210028 International Registered Report Identifier (IRRID): DERR1-10.2196/50500
- Open Access
- 4 July 2023
- Published by JMIR Publications Inc. in JMIR Preprints
The Efficacy of Carbon Dioxide Paste in Alleviating Pain in Patients After Neck Dissection: Protocol for a Double-Blinded, Randomized Controlled Trial (Preprint)
BACKGROUND Head and neck cancers that cause severe aesthetic and functional disorders normally metastasize to the cervical lymph nodes. Patients with cervical lymph node metastasis are undergoing neck dissection. Shoulder complaints are common after neck dissection, with patients reporting symptoms such as pain, weakness, shoulder droop, and disability. However, no safe and effective treatment is available for this condition at present. We will conduct a double-blinded, randomized controlled trial to evaluate the efficacy of carbon dioxide (CO2) paste in relieving pain in patients after neck dissection. OBJECTIVE This will be the first clinical study to compare the efficacy of CO2 paste with placebo in relieving postoperative pain in patients who underwent neck dissection. METHODS We will perform this trial at the Kobe University Hospital in Japan. Patients will be randomized 1:1 into the CO2 paste and control groups. Patients in the CO2 paste group will have the CO2 paste applied to the cervical surface skin for 10 minutes once per day for 14 consecutive days. The primary end point of the study is a change in the visual analog scale (VAS) scores of neck pain from baseline on day 1 (preapplication) to the end of drug application (day 15). Secondary end points include changes in the following parameters from baseline on day 1 to the end of drug application (day 15) or the study (day 29): neck pain VAS score (days 1-29), grip strength (days 1-15 and 1-29), VAS scores for subjective symptoms (the feeling of strangulation, numbness, swelling, and warmth in the neck and shoulder region) for days 1-15 and 1-29, whether the VAS score improved more than 30% (days 1-15), the arm abduction test (days 1-15 and 1-29), shoulder range of motion (abduction and flexion) for days 1-15 and 1-29, occurrence of skin disorders, and occurrence of serious side effects. Periodic monitoring will be conducted for participants during the trial. This study was approved by the certified review board of Kobe University. RESULTS The intervention commenced in May 2021 and will continue until March 2024. The collected data will provide information on the efficacy of the CO2 paste treatment. The primary end point will be compared using the Wilcoxon test, with the 1-sided significance level set at 5%. Each evaluation item will be summarized. Secondary efficacy end points will be analyzed to provide additional insights into the primary analysis. Findings based on the treatment effects are expected to be submitted for publication in 2025. CONCLUSIONS This trial will provide exploratory evidence of the efficacy and safety of CO2 paste in relieving pain in patients after neck dissection. CLINICALTRIAL Japan Registry of Clinical Trials (jRCT) identifier: jRCTs051210028; https://jrct.niph.go.jp/en-latest-detail/jRCTs051210028 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/50500
- 4 July 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessThe Efficacy of Carbon Dioxide Paste in Alleviating Pain in Patients After Neck Dissection: Protocol for a Double-Blinded, Randomized Controlled Trial (Preprint)
BACKGROUND Head and neck cancers that cause severe aesthetic and functional disorders normally metastasize to the cervical lymph nodes. Patients with cervical lymph node metastasis are undergoing neck dissection. Shoulder complaints are common after neck dissection, with patients reporting symptoms such as pain, weakness, shoulder droop, and disability. However, no safe and effective treatment is available for this condition at present. We will conduct a double-blinded, randomized controlled trial to evaluate the efficacy of carbon dioxide (CO2) paste in relieving pain in patients after neck dissection. OBJECTIVE This will be the first clinical study to compare the efficacy of CO2 paste with placebo in relieving postoperative pain in patients who underwent neck dissection. METHODS We will perform this trial at the Kobe University Hospital in Japan. Patients will be randomized 1:1 into the CO2 paste and control groups. Patients in the CO2 paste group will have the CO2 paste applied to the cervical surface skin for 10 minutes once per day for 14 consecutive days. The primary end point of the study is a change in the visual analog scale (VAS) scores of neck pain from baseline on day 1 (preapplication) to the end of drug application (day 15). Secondary end points include changes in the following parameters from baseline on day 1 to the end of drug application (day 15) or the study (day 29): neck pain VAS score (days 1-29), grip strength (days 1-15 and 1-29), VAS scores for subjective symptoms (the feeling of strangulation, numbness, swelling, and warmth in the neck and shoulder region) for days 1-15 and 1-29, whether the VAS score improved more than 30% (days 1-15), the arm abduction test (days 1-15 and 1-29), shoulder range of motion (abduction and flexion) for days 1-15 and 1-29, occurrence of skin disorders, and occurrence of serious side effects. Periodic monitoring will be conducted for participants during the trial. This study was approved by the certified review board of Kobe University. RESULTS The intervention commenced in May 2021 and will continue until March 2024. The collected data will provide information on the efficacy of the CO2 paste treatment. The primary end point will be compared using the Wilcoxon test, with the 1-sided significance level set at 5%. Each evaluation item will be summarized. Secondary efficacy end points will be analyzed to provide additional insights into the primary analysis. Findings based on the treatment effects are expected to be submitted for publication in 2025. CONCLUSIONS This trial will provide exploratory evidence of the efficacy and safety of CO2 paste in relieving pain in patients after neck dissection. CLINICALTRIAL Japan Registry of Clinical Trials (jRCT) identifier: jRCTs051210028; https://jrct.niph.go.jp/en-latest-detail/jRCTs051210028 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/50500